Dana Delaski, MSN, FNP-BC, shares insights on how once-daily ruxolitinib, self-injected rusfertide, and givinostat will transform PV clinic workflows.
|Articles|January 8, 2015
CTCL Treatments - The Old and New - Part 2
Part 2 of an overview and explanation of current cutaneous lymphoma treatments.
Advertisement
Alain H. Rook, MD, Professor of Dermatology, University of Pennsylvania, Perelman School of Medicine provides part two of a three part overview of treatments for cutaneous lymphoma.
Advertisement
Related to this article
FDA approves belzutifan with lenvatinib for advanced clear cell RCC after PD-1/PD-L1 inhibitor failure. Review LITESPARK-011 data and nursing takeaways.
ANA President Jennifer Mensik Kennedy outlines systemic nurse fatigue mitigation policies, emphasizing patient safety and acuity across oncology care.
From ICN 2026, Heather Jackson and Ashley Johnson detail APP breast care access models, global cancer pain barriers, and burnout mitigation tactics.
FDA approves lirafugratinib (Lyrfigtu) for FGFR2+ cholangiocarcinoma. Review REFOCUS trial data, 70 mg daily dosing, and nursing safety guidelines.
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.
Yesne Alici, MD, of Memorial Sloan Kettering Cancer Center discusses key delirium screening, patient capacity, and bioethics in oncology nursing care.
A nurse-led support program significantly reduces death anxiety in women with breast cancer on hormonal therapy, study finds.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced Clear Cell RCC
2
ICN 2026: APP Leadership, Cancer Pain Care, and Nurse-Led Rapid Care Models
3
FDA Approves Lirafugratinib for Advanced FGFR2+ Cholangiocarcinoma
4
How On-Body Treatment Delivery Reduces Nursing Burden in Myeloma Care
5